**Tessel Rigter**
**Research Associate, Lecturer**
**Clinical genetics**

## Contact information

UNIVERSITY: Amsterdam UMC
DEPARTMENT: Human Genetics & Amsterdam Public Health research institute
LOCATION: VU University Medical Center, Medical Faculty
VISITING ADDRESS: Van der Boechorststraat 7, Room G130
POSTAL ADDRESS: BS7/G102, PO Box 7057, 1007 MB Amsterdam
TELEPHONE: 020-4445507
E-MAIL: t.rigter@vumc.nl

## Profile

Inquisitive researcher with a PhD in “Translating the dynamics of genetics into health care practice”, and experience in policy-informing studies. Skilled in translational research, qualitative study design, scientific writing, and teaching. Creating impact by building bridges, stimulating knowledge exchange, and defining strategies for optimization and change in the field of Public Health Genomics.

## Experience

**Research associate**
Human genetics
VU University medical center
2009 – Present

**Program leader**
Personalized Medicine programme
Amsterdam Public Health Institute (APH)
2021 - present

**Lecturer**
Clinical genetics
VU University medical center
2011 – Present

**Junior board member**
Personalized Medicine programme
Amsterdam Public Health Institute (APH)
2018 - 2021

**Working group manager “Methodology of determining value of predictive tests”**
ZonMW Programme personalized medicine
National Institute for Public Health and the Environment (RIVM)
2018 – 2020

**PhD Candidate**
EMGO - Quality of care
VU University medical center
2009 – 2013

**Biology Teacher**
Utrechts stedelijk gymnasium
2009

## Education

**PhD** Translating the dynamics of genetics into health care practice, VUmc |Amsterdam, 2014

**MSc** Science communication, UU | Utrecht,2008

**MSc** Science teacher education (in biology), UU | Utrecht, 2008

**BSc** Biomedical sciences, UU | Utrecht, 2005

## Professional training

Course **Acquisition** (by InZicht Training), 2018

Course **Medical Technology Assesment** (by DutchCC), 2015

**Early stage researchers' network** workshop (by University of Oxford), 2014

Seminar **Orphan drugs in Europe** (by DutchCC), 2014

Advanced course: **Translational genomics pipeline: from populations to individuals** (by Wellcome Trust, Cambridge), 2012

**University Teaching Qualification** (by VUmc), 2012

**AtlasTI**, beginners and advanced course (by Evers Research and Training), 2011

**Writing a Scientific Article** (by VU University), 2010

## Professional societies

**NACGG** Nederlandse Associatie voor Community Genetics en Public Health Genomics
(member since 2011)

**ESHG** European Society of Human Genetics (member since 2012)

**NVHG** Nederlandse Vereniging voor Humane Genetica (member since 2013)

**NNPM** Netherlands Network for Precision Medicine (member since 2017)

## Research outputs

**Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe**
Rigter, T., Klein, D., Weinreich, S. S. & Cornel, M. C., Oct 2021, In: European Journal of Human Genetics. 29, 10, p. 1477-1484 8 p.

**Towards a Responsible Transition to Learning Healthcare Systems in Precision Medicine: Ethical Points to Consider**
Wouters, R. H. P., van der Graaf, R., Rigter, T., Bunnik, E. M., Ploem, M. C., de Wert, G. M. W. R., Dondorp, W. J., Cornel, M. C. & Bredenoord, A. L., 10 Jun 2021, In: Journal of personalized medicine. 11, 6, 539.

**Clinical genetics in transition—a comparison of genetic services in Estonia, Finland, and the Netherlands**
Vrijenhoek, T., Tonisson, N., Kääriäinen, H., Leitsalu, L. & Rigter, T., Apr 2021, In: Journal of Community Genetics. 12, 2, p. 277-290 14 p.

**Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide**
Cornel, M. C., Rigter, T., Jansen, M. E. & Henneman, L., Apr 2021, In: Journal of Community Genetics. 12, 2, p. 257-265 9 p.

**Opportunistische farmacogenetische screening DNA-data gebruiken die al beschikbaar zijn**
Jansen, M. E., Rigter, T. & de Wert, G. M. W. R., 1 Feb 2021, In: Nederlands Tijdschrift voor Geneeskunde. 165, 7, D5130.

**Roles and Responsibilities of Stakeholders in Informing Healthy Individuals on Their Genome: A Sociotechnical Analysis**
Cornel, M. C., Rigter, T. & van el, C. G., 2021, *SpringerBriefs in Public Health.* Springer, p. 77-94 18 p. (SpringerBriefs in Public Health).

**Opportunistic screening for actionable pharmacogenetic variants: why not apply knowledge to patient-data that is already available?**
Rigter, T., Jansen, M. E., de Wert, G. M. W. R. & Cornel, M. C., Dec 2020, In: European Journal of Human Genetics. 28, SUPPL 1, p. 792-793

**Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective**
Rigter, T., Jansen, M. E., Groot, J. M. D., Janssen, S. W. J., Rodenburg, W. & Cornel, M. C., 31 Jan 2020, In: Frontiers in Genetics. 11, 10.

**DPD testing before treatment with fluoropyrimidines in the Amsterdam UMCs: An evaluation of current pharmacogenetic practice**
Martens, F. K., Huntjens, D. W., Rigter, T., Bartels, M., Bet, P. M. & Cornel, M. C., 28 Jan 2020, In: Frontiers in Pharmacology. 10, 1609.

**Next Generation Sequencing in health care and clinical research: attuning all steps**
Rigter, T., Belien, J. A. M., de Wert, G. M. W. R., Ploem, C., Bunnik, E. M., Bredenoord, A. L. & Cornel, M. C., Oct 2019, In: European Journal of Human Genetics. 27, p. 1790-1791

**SLCO1B1 c.521T > C genotype, sex, and initial statin treatment as contributing factors to continuous simvastatin or atorvastatin treatment in a Dutch cohort**
Jansen, M. E., Rigter, T., Fleur, T. M. C., Souverein, P., Vijverberg, S. J. H., Rodenburg, W. & Cornel, M. C., Jul 2019, In: European Journal of Human Genetics. 27, p. 558-559

**Actions, roles, and responsibilities in implementation of pharmacogenomics in primary care**
Jansen, M. E., Rigter, T., Janssen, S., Rodenburg, W. & Cornel, M. C., Oct 2018, In: European Journal of Human Genetics. 26, p. 687-688

**Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing: A case study of statin-induced muscle toxicity**
Jansen, M. E., Rigter, T., Rodenburg, W., Fleur, T. M. C., Houwink, E. J. F., Weda, M. & Cornel, M. C., 23 Aug 2017, In: Frontiers in Pharmacology. 8, AUG, 555.

**Stakeholder perspectives on the implementation of genetic carrier screening in a changing landscape**
Holtkamp, K. C. A., Vos, E. M., Rigter, T., Lakeman, P., Henneman, L. & Cornel, M. C., 16 Feb 2017, In: BMC Health Services Research. 17, 1, 146.

**Challenges and opportunities for ELSI early career researchers: Bmc Medical Ethics**
Bell, J., Ancillotti, M., Coathup, V., Coy, S., Rigter, T., Tatum, T., Grewal, J., Akcesme, F. B., Brkic, J., Causevic-Ramosevac, A., Milovanovic, G., Nobile, M., Pavlidis, C., Finlay, T., Kaye, J. & [Unknown], E., 2016, In: BMC Medical Ethics. 17, 1 p., 37.

**A decade of molecular genetic testing for MODY: a retrospective study of utilization in The Netherlands**
Weinreich, S. S., Bosma, A. R., Henneman, L., Rigter, T., Spruijt, C. M. J., Grimbergen, A. J. E. M., Breuning, M. H., de Koning, E. J. P., Losekoot, M. & Cornel, M. C., 2015, In: European Journal of Human Genetics. 23, 1, p. 29-33

**A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members**
Bosma, A. R., Rigter, T., Weinreich, S. S., Cornel, M. C. & Henneman, L., 2015, In: Diabetic Medicine. 32, 10, p. 1385-1392

**Current and Best Practices of Genetic Testing for Maturity Onset Diabetes of the Young: Views of Professional Experts**
van der Zwaag, A. M., Weinreich, S. S., Bosma, A. R., Rigter, T., Losekoot, M., Henneman, L. & Cornel, M. C., 2015, In: Public Health Genomics. 18, 1, p. 52-59

**Farmacogenetica in de eerstelijnszorg. Toepassingen en toekomstverwachtingen**
Houwink, E. J. F., Rigter, T., Swen, J. J., Cornel, M. C., Kienhuis, A., Rodenburg, W. & Weda, M., 2015, In: Nederlands Tijdschrift voor Geneeskunde. 159, A9204.

**A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document**
Cornel, M. C., Rigter, T., Weinreich, S. S., Burgard, P., Hoffmann, G. F., Lindner, M., Loeber, J. G., Rupp, K., Taruscio, D. & Vittozzi, L., 2014, In: European Journal of Human Genetics. 22, 1, p. 12-17

**Developing a framework for implementation of genetic services: learning from examples of testing for monogenic forms of common diseases**
Rigter, T., Henneman, L., Broerse, J. E. W., Shepherd, M., Blanco, I., Kristoffersson, U. & Cornel, M. C., 2014, In: Journal of Community Genetics. 5, 4, p. 337-347

**Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients**
Rigter, T., van Aart, C. J. A., Elting, M. W., Waisfisz, Q., Cornel, M. C. & Henneman, L., 2014, In: Clinical Genetics. 85, 5, p. 417-422

**Newborn screening for pompe disease? a qualitative study exploring professional views**
van El, C. G., Rigter, T., Reuser, A. J. J., van der Ploeg, A. T., Weinreich, S. S. & Cornel, M. C., 2014, In: BMC Pediatrics. 14, 203.

**Translating the dynamics of genetics into health care practice**
Rigter, T., 2014

**Reflecting on Earlier Experiences with Unsolicited Findings: Points to Consider for Next-Generation Sequencing and Informed Consent in Diagnostics**
Rigter, T., Henneman, L., Kristoffersson, U., Hall, A., Yntema, H. G., Borry, P., Tonnies, H., Waisfisz, Q., Elting, M. W., Dondorp, W. J. & Cornel, M. C., 2013, In: Human Mutation. 34, 10, p. 1322-1328

**Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result**
Loeber, J. G., Burgard, P., Cornel, M. C., Rigter, T., Weinreich, S. S., Rupp, K., Hoffmann, G. F. & Vittozzi, L., 2012, In: Journal of Inherited Metabolic Disease. 35, 4, p. 603-611

**Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance**
Burgard, P., Rupp, K., Lindner, M., Haege, G., Rigter, T., Weinreich, S. S., Loeber, J. G., Taruscio, D., Vittozzi, L., Cornel, M. C. & Hoffmann, G. F., 2012, In: Journal of Inherited Metabolic Disease. 35, 4, p. 613-625

**Public support for neonatal screening for Pompe disease, a broad-phenotype condition**
Weinreich, S. S., Rigter, T., van El, C. G., Dondorp, W. J., Kostense, P. J., van der Ploeg, A. T., Reuser, A. J., Cornel, M. C. & Hagemans, M. L., 2012, In: Orphanet Journal of Rare Diseases. 7, 15.

**Severely impaired health status at diagnosis of Pompe disease: A cross-sectional analysis to explore the potential utility of neonatal screening**
Rigter, T., Weinreich, S. S., van El, C. G., de Vries, J. M., van Gelder, C. M., Gungor, D., Reuser, A. J. J., Hagemans, M. L. C., Cornel, M. C. & van der Ploeg, A. T., 2012, In: Molecular Genetics and Metabolism. 107, 3, p. 448-455